The Wall Street Journal @WSJ
A long-running trial of an experimental Alzheimer’s drug in people at high risk of developing the mind-robbing disease at a young age has failed to prevent the development of early symptoms, in another knock back for a field marked by disappointments https://t.co/rwjYetM5NZ — PolitiTweet.org